Logo

SSKN

STRATA Skin Sciences, Inc.

SSKN

STRATA Skin Sciences, Inc. • NASDAQ
$1.50 ▲ 10.29% (+0.14)
Market Cap $6.38 M
52w High $3.86
52w Low $1.24
Dividend Yield 0%
P/E -0.57
Volume 34.67K
Outstanding Shares 4.25M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $6.929M ▼ $6.041M ▼ $-1.622M ▲ -23.409% ▲ $-0.36 ▲ $-173K ▲
Q2-2025 $7.663M ▲ $6.53M ▲ $-2.489M ▼ -32.481% ▲ $-0.6 ▼ $-693K ▼
Q1-2025 $6.812M ▼ $5.662M ▼ $-2.432M ▲ -35.702% ▲ $-0.058 ▲ $-641K ▲
Q4-2024 $9.576M ▲ $9.984M ▲ $-4.497M ▼ -46.961% ▼ $-0.12 ▼ $-2.838M ▼
Q3-2024 $8.797M $6.96M $-2.122M -24.122% $-0.052 $-265K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $7.076M ▲ $30.717M ▼ $29.403M ▼ $1.314M ▲
Q2-2025 $5.966M ▼ $30.722M ▼ $30.414M ▼ $308K ▼
Q1-2025 $6.512M ▼ $34.262M ▼ $31.593M ▲ $2.669M ▼
Q4-2024 $7.261M ▲ $36.157M ▼ $31.185M ▲ $4.972M ▼
Q3-2024 $7.062M $40.205M $30.862M $9.343M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-1.622M ▲ $-64K ▲ $-1.018M ▼ $2.192M ▲ $1.11M ▲ $-1.082M ▲
Q2-2025 $-2.489M ▼ $-1.941M ▼ $61K ▲ $0 $-1.88M ▼ $-1.88M ▼
Q1-2025 $-2.432M ▲ $-550K ▼ $-199K ▲ $0 $-749K ▼ $-749K ▼
Q4-2024 $-4.497M ▼ $703K ▲ $-504K ▼ $0 ▼ $199K ▼ $199K ▲
Q3-2024 $-2.122M $-302K $-62K $1.943M $1.579M $-364K

Revenue by Products

Product Q2-2024Q3-2024Q4-2024Q1-2025
Dermatology Procedures Equipment
Dermatology Procedures Equipment
 $0 ▲$0 ▲$0 ▲$0 ▲
Dermatology Recurring Procedures
Dermatology Recurring Procedures
 $10.00M ▲$10.00M ▲$10.00M ▲$0 ▼

Five-Year Company Overview

Income Statement

Income Statement Revenue has been relatively small and mostly flat over the past several years, with only modest growth and no clear upward momentum. The company usually generates a reasonable gross margin on what it sells, but operating costs eat up most of that, leaving operating results slightly in the red recently. Net income has been negative for the last few years after being closer to break-even before, and per‑share losses have widened, which suggests pressure from costs and limited scale rather than strong, profitable growth.

Balance Sheet

Balance Sheet The balance sheet looks thin. Total assets have stayed fairly steady, but the cash balance is modest and not building, and debt has crept up compared with earlier years. Shareholders’ equity has eroded over time and is now very small, reflecting accumulated losses and leaving a limited financial cushion. Combined with a history of reverse stock splits, this points to a business that has had difficulty sustaining value and has relatively little balance‑sheet flexibility.

Cash Flow

Cash Flow Operating cash flow has hovered around breakeven, which means the core business roughly funds itself but does not consistently generate surplus cash to reinvest or reduce debt. Free cash flow has occasionally dipped slightly negative when the company invested in equipment or other capital needs. Overall, cash generation is fragile: not clearly deteriorating, but not strong enough to comfortably support aggressive growth or weather prolonged downturns without tapping external financing.

Competitive Edge

Competitive Edge STRATA focuses on a narrow but defensible niche in dermatology devices, centered on its XTRAC laser for conditions like psoriasis and vitiligo and its TheraClearX system for acne. Its main strengths are a sizable installed base in U.S. dermatology clinics, a per‑treatment recurring revenue model, and a patent portfolio that helps protect its technology and combinations with certain drugs. Favorable legal outcomes against a competitor and broad insurance coverage in the U.S. reinforce its position. On the other hand, it still competes in a crowded treatment landscape that includes drugs, other devices, and topical therapies, and its business is highly exposed to reimbursement decisions and clinic utilization levels, which have already shown some softness internationally.

Innovation and R&D

Innovation and R&D The company’s innovation is centered on improving and extending its existing platforms rather than spreading into many new areas. XTRAC offers targeted UV light therapy with protocols designed to speed results and reduce side effects versus older phototherapy methods, while TheraClearX provides a non‑drug acne option using combined vacuum and light. STRATA is actively building clinical evidence and pursuing new treatment indications and reimbursement codes, especially for additional skin conditions beyond psoriasis, which could significantly expand its addressable market if realized. The patent portfolio around technology and combination therapies, along with new clearances such as in Mexico, shows continued development, but success depends on regulatory and reimbursement approvals and on converting clinical promise into sustained commercial adoption.

Summary

STRATA Skin Sciences is a small, specialized medical device company with differentiated dermatology technologies and a recurring, clinic‑based business model. Its strategic story—more indications, broader reimbursement, and deeper use of its installed devices—is appealing, and it has some tangible competitive assets in patents, clinical data, and an established clinic network. At the same time, the financial profile is delicate: revenue is flat, profits are negative, equity is thin, and cash generation is only marginally supportive. Future outcomes hinge on execution: stabilizing the core XTRAC business, scaling TheraClearX, successfully expanding reimbursement coverage, and managing debt and costs without much balance‑sheet room for error.

NEWS

November 6, 2025 · 8:00 AM UTC

STRATA Skin Sciences Announces CMS Recognition of Expanded CPT Codes for Inflammatory and Autoimmune Dermatologic Conditions with Company Anticipating Wider Excimer Adoption Ahead Of 2027 CPT Expansion

Read more

November 5, 2025 · 8:00 AM UTC

STRATA Skin Sciences to Report Third Quarter 2025 Financial Results on November 13, 2025 and Provide Corporate Update

Read more

October 14, 2025 · 8:15 AM UTC

Excimer Laser Demonstrates Promising Results in Treating Rare Variant of Cutaneous Lymphoma, Mycosis Fungoides

Read more

October 3, 2025 · 10:50 AM UTC

Marking Eczema Awareness Month – Clinical Research Validates Strata Skin Sciences' XTRAC® Excimer Laser as a Breakthrough Therapy for Localized Atopic Dermatitis

Read more

September 30, 2025 · 8:15 AM UTC

STRATA Skin Sciences Receives Continued Validation for its Personalized Approach with New Published Study Highlighting XTRAC® Excimer Laser Treatment Combined with a Topical Drug in Psoriasis

Read more